Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease

Movement Disorders

Volumn 20, Issue 1, 2005, Pages 77-81

  Pezzella, Francesca Romana ^a   Colosimo, Carlo ^a   Vanacore, Nicola ^b   Di Rezze, Simone ^a   Chianese, Melania ^a   Fabbrini, Giovanni ^a   Meco, Giuseppe ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Addiction; Dopamine; Levodopa; Parkinson's disease

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ADULT; AGED; ANAMNESIS; ARTICLE; BEHAVIOR DISORDER; CASE CONTROL STUDY; CLINICAL FEATURE; COMPULSION; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURAL FACTOR; DEPRESSION; DRUG DEPENDENCE; ENVIRONMENTAL FACTOR; FEMALE; HEDONISTIC HOMEOSTATIC DYSREGULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MONOTHERAPY; MOOD DISORDER; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COMPULSIVE BEHAVIOR; DOPAMINE AGONISTS; FEMALE; HOMEOSTASIS; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; NERVOUS SYSTEM DISEASES; PARKINSON DISEASE; PREVALENCE; QUESTIONNAIRES; SELF MEDICATION; STATISTICS, NONPARAMETRIC; VIOLENCE;

EID: 14044253562     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20288     Document Type: Article

References (25)

1. Burn DJ. Depression in Parkinson's disease. Eur J Neurol 2002; 9(Suppl. 3):44-54.
2. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000;68:423-428.
3. Gibb WR, Lees AJ. The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. Neuropathol Appl Neurobiol 1989;15:27-44.
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. DSM-IV, 4th ed. Washington, DC: American Psychiatric Association; 1994.
5. Pezzella FR, Di Rezze S, Chianese M, et al. Hedonistic homeostatic dysregulation in Parkinson's disease: a short screening questionnaire. Neurol Sci 2003;24:205-206.
6. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
7. Fahn S, Elton RL, UPDRS program members. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, editors. Recent developments in Parkinson's disease. Vol. 2. Florham Park, NJ: Macmillan Healthcare Information; 1987. p 153-163.
8. Dekker M, Bonifati V, van Swieten J, et al. Clinical features and neuroimaging of PARK7-linked parkinsonism. Mov Disord 2003; 18:751-757.
9. Schultz W. Getting formal with dopamine and reward. Neuron. 2002;36:241-263.
10. Martin-Soelch C, Leenders KL, Chevalley AF, et al. Reward mechanisms in the brain and their role in dependence: evidence from neurophysiological and neuroimaging studies. Brain Res Rev 2001;36:139-149.
11. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388: 839-840.
12. Mash DC, Ouyang Q, Pablo J, et al. Cocaine abusers have an overexpression of alpha-synuclein in dopamine neurons. J Neurosci 2003;23:2564-2571.
13. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward system gone awry? Lancet Neurol 2003;2:595-604.
14. Nausieda PA. Sinemet "abusers". Clin Neuropharmacol 1985;8: 318-327.
15. Vogel HP, Schiffter R. Hypersexuality-a complication of dopaminergic therapy in Parkinson's disease. Pharmacopsychiatria 1983; 16:107-110.
16. Spigset O, von Scheele C. Levodopa dependence and abuse in Parkinson's disease. Pharmacotherapy 1997;17:1027-1030.
17. Soyka M, Huppert D. L-dopa abuse in a patient with former alcoholism. Br J Addict 1992;87:117-188.
18. Priebe S. Levodopa dependence: a case report. Pharmacopsychiatry 1984;17:109-110.
19. Maricle RA, Valentine RJ, Carter J, Nutt JG. Mood response to levodopa infusion in early Parkinson's disease. Neurology 1998; 50:1890-1892.
20. Muller U, Reuter M, Hermann W, Gertz HJ. Levodopa dependency in Parkinson's disease: case report and review. Nervenarzt 2002; 73:887-891.
21. Gschwandtner U, Aston J, Renaud S, Fuhr P. Pathologic gambling in patients with Parkinson's disease. Clin Neuropharmacol 2001; 24:170-172.
22. Molina JA, Sainz-Artiga MJ, Fraile A, et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment? Mov Disord 2000;15:869-872.
23. Driver-Dunckleys E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003;61:422-423.
24. Betchen SA, Kaplitt M, Future and current surgical therapies in Parkinson's disease. Curr Opin Neurol 2003;16:487-493.
25. Zappia M, Crescibene L, Arabia G, et al. Body weight influences pharmacokinetics of levodopa in Parkinson's disease. Clin Neuropharmacol 2002;25:79-82.